Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Alejandro Zapata

Psychiatry Sterling Heights, MI Medical Doctor

NPI 1467461855 CMS profile 201987

5528 Metropolitan Pkwy, Sterling Heights, MI 48310

Open in the dashboard

General payments

$8,879

374 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Alejandro Zapata of Sterling Heights, MI is reported in the CMS Open Payments database as having received $8,879 across 374 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,121 37
2022 General $2,241 71
2021 General $2,648 97
2020 General $1,450 67
2019 General $1,420 102

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alejandro Zapata
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Alejandro Zapata were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Alejandro Zapata Psychiatry median Middle half National median
2019 $1,420 $184 $59–$605 $163
2020 $1,450 $119 $36–$372 $114
2021 $2,648 $143 $43–$576 $132
2022 $2,241 $153 $50–$590 $149
2023 $1,121 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Otsuka America Pharmaceutical, Inc. $1,467 47 payments
  2. Alkermes, Inc. $1,359 42 payments
  3. Janssen Pharmaceuticals, Inc $877 52 payments
  4. Sunovion Pharmaceuticals Inc. $873 53 payments
  5. ITI, Inc. $768 15 payments
  6. Neurocrine Biosciences, Inc. $581 12 payments
  7. AbbVie, Inc. $549 21 payments
  8. Lundbeck LLC $523 33 payments
  9. Allergan Inc. $355 36 payments
  10. Validus Pharmaceuticals LLC $245 9 payments
  11. Other $1,282 54 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $8,819 372 payments
  2. Education $60 2 payments
Products named General payments · program years 2019–2023
  1. REXULTI $1,256 40 payments
  2. LATUDA $873 53 payments
  3. LYBALVI Cns $834 26 payments
  4. INVEGA SUSTENNA $833 51 payments
  5. ARISTADA Cns $788 34 payments
  6. ARISTADA Cns $788 34 payments
  7. CAPLYTA $768 15 payments
  8. LYBALVI Cns $764 23 payments
  9. ARISTADA INITIO $718 31 payments
  10. ARISTADA Cns $595 19 payments
  11. Other $6,210 250 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

374 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record